A novel core fractionation process of human plasma by expanded bed adsorption chromatography

Allan Lihme, Marie Bendix Hansen, Inga Vaarst Andersen, Thierry Burnouf

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Current plasma fractionation technology combines ethanol precipitation with packed bed chromatography. We have developed a novel core fractionation process comprising five expanded bed adsorption (EBA) chromatographic steps on high-density modified agarose/tungsten carbide beads. Plasma was first chromatographed on two diethyl amino-ethyl (DEAE)-tungsten carbide agarose adsorbents (respective mean particle diameters of dv(0.5)=190 and 37μm) to isolate at 50 to 80% recovery a fraction containing 4 to 7IU/ml factor II (FII), factor IX (FIX), and factor X (FX) (specific activity >1IU/mg) and another enriched in FVIII and von Willebrand factor (vWF) (∼1IU/ml and 0.6IU/mg, respectively). The flow-through was adsorbed on 4% agarose-10% tungsten carbide beads coupled with an acidic mixed-mode ligand to isolate an 80% pure immunoglobulin G (IgG) at a 93% step recovery. A highly purified α1-antitrypsin was isolated at 95% step recovery by adsorbing the flow-through on 4% epoxy-crosslinked agarose-10% tungsten carbide adsorbent material coupled with a cationic ligand. Isolation of 98% pure albumin was achieved at a 99% step recovery by pH 4.5 adsorption of the flow-through on 6% agarose-10% tungsten carbide beads coupled with an acidic mixed-mode ligand. EBA may represent a feasible alternative core plasma fractionation tool.

Original languageEnglish
Pages (from-to)102-109
Number of pages8
JournalAnalytical Biochemistry
Volume399
Issue number1
DOIs
Publication statusPublished - Apr 2010
Externally publishedYes

Fingerprint

Plasma (human)
Fractionation
Chromatography
Sepharose
Adsorption
Recovery
Ligands
Plasmas
Adsorbents
Factor X
Factor IX
von Willebrand Factor
Packed beds
Prothrombin
Albumins
Ethanol
Immunoglobulin G
tungsten carbide
Technology

Keywords

  • α1-Antitrypsin
  • Albumin
  • Expanded bed chromatography
  • Factor VIII
  • Fractionation
  • Immunoglobulins
  • Plasma
  • Prothrombin complex
  • Von Willebrand factor

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

A novel core fractionation process of human plasma by expanded bed adsorption chromatography. / Lihme, Allan; Hansen, Marie Bendix; Andersen, Inga Vaarst; Burnouf, Thierry.

In: Analytical Biochemistry, Vol. 399, No. 1, 04.2010, p. 102-109.

Research output: Contribution to journalArticle

Lihme, Allan ; Hansen, Marie Bendix ; Andersen, Inga Vaarst ; Burnouf, Thierry. / A novel core fractionation process of human plasma by expanded bed adsorption chromatography. In: Analytical Biochemistry. 2010 ; Vol. 399, No. 1. pp. 102-109.
@article{c804f031de0743b8916c05d108fbd6c4,
title = "A novel core fractionation process of human plasma by expanded bed adsorption chromatography",
abstract = "Current plasma fractionation technology combines ethanol precipitation with packed bed chromatography. We have developed a novel core fractionation process comprising five expanded bed adsorption (EBA) chromatographic steps on high-density modified agarose/tungsten carbide beads. Plasma was first chromatographed on two diethyl amino-ethyl (DEAE)-tungsten carbide agarose adsorbents (respective mean particle diameters of dv(0.5)=190 and 37μm) to isolate at 50 to 80{\%} recovery a fraction containing 4 to 7IU/ml factor II (FII), factor IX (FIX), and factor X (FX) (specific activity >1IU/mg) and another enriched in FVIII and von Willebrand factor (vWF) (∼1IU/ml and 0.6IU/mg, respectively). The flow-through was adsorbed on 4{\%} agarose-10{\%} tungsten carbide beads coupled with an acidic mixed-mode ligand to isolate an 80{\%} pure immunoglobulin G (IgG) at a 93{\%} step recovery. A highly purified α1-antitrypsin was isolated at 95{\%} step recovery by adsorbing the flow-through on 4{\%} epoxy-crosslinked agarose-10{\%} tungsten carbide adsorbent material coupled with a cationic ligand. Isolation of 98{\%} pure albumin was achieved at a 99{\%} step recovery by pH 4.5 adsorption of the flow-through on 6{\%} agarose-10{\%} tungsten carbide beads coupled with an acidic mixed-mode ligand. EBA may represent a feasible alternative core plasma fractionation tool.",
keywords = "α1-Antitrypsin, Albumin, Expanded bed chromatography, Factor VIII, Fractionation, Immunoglobulins, Plasma, Prothrombin complex, Von Willebrand factor",
author = "Allan Lihme and Hansen, {Marie Bendix} and Andersen, {Inga Vaarst} and Thierry Burnouf",
year = "2010",
month = "4",
doi = "10.1016/j.ab.2009.12.002",
language = "English",
volume = "399",
pages = "102--109",
journal = "Analytical Biochemistry",
issn = "0003-2697",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - A novel core fractionation process of human plasma by expanded bed adsorption chromatography

AU - Lihme, Allan

AU - Hansen, Marie Bendix

AU - Andersen, Inga Vaarst

AU - Burnouf, Thierry

PY - 2010/4

Y1 - 2010/4

N2 - Current plasma fractionation technology combines ethanol precipitation with packed bed chromatography. We have developed a novel core fractionation process comprising five expanded bed adsorption (EBA) chromatographic steps on high-density modified agarose/tungsten carbide beads. Plasma was first chromatographed on two diethyl amino-ethyl (DEAE)-tungsten carbide agarose adsorbents (respective mean particle diameters of dv(0.5)=190 and 37μm) to isolate at 50 to 80% recovery a fraction containing 4 to 7IU/ml factor II (FII), factor IX (FIX), and factor X (FX) (specific activity >1IU/mg) and another enriched in FVIII and von Willebrand factor (vWF) (∼1IU/ml and 0.6IU/mg, respectively). The flow-through was adsorbed on 4% agarose-10% tungsten carbide beads coupled with an acidic mixed-mode ligand to isolate an 80% pure immunoglobulin G (IgG) at a 93% step recovery. A highly purified α1-antitrypsin was isolated at 95% step recovery by adsorbing the flow-through on 4% epoxy-crosslinked agarose-10% tungsten carbide adsorbent material coupled with a cationic ligand. Isolation of 98% pure albumin was achieved at a 99% step recovery by pH 4.5 adsorption of the flow-through on 6% agarose-10% tungsten carbide beads coupled with an acidic mixed-mode ligand. EBA may represent a feasible alternative core plasma fractionation tool.

AB - Current plasma fractionation technology combines ethanol precipitation with packed bed chromatography. We have developed a novel core fractionation process comprising five expanded bed adsorption (EBA) chromatographic steps on high-density modified agarose/tungsten carbide beads. Plasma was first chromatographed on two diethyl amino-ethyl (DEAE)-tungsten carbide agarose adsorbents (respective mean particle diameters of dv(0.5)=190 and 37μm) to isolate at 50 to 80% recovery a fraction containing 4 to 7IU/ml factor II (FII), factor IX (FIX), and factor X (FX) (specific activity >1IU/mg) and another enriched in FVIII and von Willebrand factor (vWF) (∼1IU/ml and 0.6IU/mg, respectively). The flow-through was adsorbed on 4% agarose-10% tungsten carbide beads coupled with an acidic mixed-mode ligand to isolate an 80% pure immunoglobulin G (IgG) at a 93% step recovery. A highly purified α1-antitrypsin was isolated at 95% step recovery by adsorbing the flow-through on 4% epoxy-crosslinked agarose-10% tungsten carbide adsorbent material coupled with a cationic ligand. Isolation of 98% pure albumin was achieved at a 99% step recovery by pH 4.5 adsorption of the flow-through on 6% agarose-10% tungsten carbide beads coupled with an acidic mixed-mode ligand. EBA may represent a feasible alternative core plasma fractionation tool.

KW - α1-Antitrypsin

KW - Albumin

KW - Expanded bed chromatography

KW - Factor VIII

KW - Fractionation

KW - Immunoglobulins

KW - Plasma

KW - Prothrombin complex

KW - Von Willebrand factor

UR - http://www.scopus.com/inward/record.url?scp=77649189816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649189816&partnerID=8YFLogxK

U2 - 10.1016/j.ab.2009.12.002

DO - 10.1016/j.ab.2009.12.002

M3 - Article

C2 - 19995544

AN - SCOPUS:77649189816

VL - 399

SP - 102

EP - 109

JO - Analytical Biochemistry

JF - Analytical Biochemistry

SN - 0003-2697

IS - 1

ER -